橋本 学 (ハシモト マナブ)

HASHIMOTO Manabu

写真a

所属

大学院医学系研究科(医学専攻等)  医学専攻  病態制御医学系  放射線医学講座

研究分野・キーワード

放射線医学

出身大学 【 表示 / 非表示

  •  
    -
    1982年03月

    秋田大学   医学部   卒業

取得学位 【 表示 / 非表示

  • 秋田大学 -  医学博士

職務経歴(学内) 【 表示 / 非表示

  • 2009年11月
    -
    継続中

    秋田大学   大学院医学系研究科(医学専攻等)   医学専攻   病態制御医学系   教授  

 

論文 【 表示 / 非表示

  • Long-term Outcomes of Hypofractionated Stereotactic Radiotherapy for the Treatment of Perioptic Nonfunctioning Pituitary Adenomas

    HATA Aiko, SHIMIZU Hiroaki, ODA Masaya, ONO Takahiro, SUZUKI Akira, HANYU Noriaki, TAKAHASHI Masataka, SASAJIMA Toshio, HASHIMOTO Manabu, NAKASE Taizen

    Neurologia medico-chirurgica ( 一般社団法人 日本脳神経外科学会 )    2021年

    ISSN:0470-8105

    <p>The efficacy of stereotactic radiotherapy (SRT) has been well established for postoperative residual and recurrent nonfunctioning pituitary adenomas (NFPAs). However, the risk of visual impairment due to SRT for lesions adjacent to the optic pathways remains a topic of debate. Herein, we evaluated the long-term clinical outcomes of hypofractionated stereotactic radiotherapy (HFSRT) for perioptic NFPAs. From December 2002 to November 2015, 32 patients (18 males and 14 females; median age 63 years; range, 36–83 years) with residual or recurrent NFPAs abutting or displacing the optic nerve and/or chiasm (ONC) were treated with HFSRT. The median marginal dose was 31.3 Gy (range, 17.2–39.6) in 8 fractions (range, 6–15). Magnetic resonance imaging (MRI) and visual and hormonal examinations were performed before and after HFSRT. The median follow-up period was 99.5 months (range, 9–191). According to MRI findings at the last follow-up, the tumor size had decreased in 28 (88%) of 32 patients, was unchanged in 3 (9%), and had increased in 1 (3%). The successful tumor size control rate was 97%. Visual functions remained unchanged in 19 (60%) out of 32 patients, improved in 11 (34%), and deteriorated in 2 (6%). Two patients had deteriorated visual functions; no complications occurred because of the HFSRT. One patient developed hypopituitarism that required hormone replacement therapy. The result of this long-term follow-up study suggests that HFSRT is safe and effective for the treatment of NFPAs occurring adjacent to the ONC.</p>

    DOI CiNii

  • Modern evidence and future prospects of external body radiation therapy for lung oligometastases of breast cancer

    Wada Y.

    Translational Cancer Research ( Translational Cancer Research )  9 ( 8 ) 5077 - 5086   2020年08月

    ISSN:2218676X

    DOI

  • Initial experience of high-dose helical tomotherapy for medically inoperable esophageal cancer patients

    Tate Etsuko, Hama Yukihiro, Hashimoto Manabu

    Personalized Medicine Universe ( 一般社団法人 国際個別化医療学会 )  9 ( 0 ) 15 - 19   2020年

    ISSN:2186-4969

    <p>Purpose: Helical tomotherapy (HT) is one of the radiotherapy methods that has become widespread in recent years. The aim of this study is to investigate the safety of high-dose HT for medically inoperable esophageal cancer that is unable to tolerate chemoradiotherapy.</p><p>Methods: Eight patients with medically inoperable esophageal squamous cell carcinoma who cannot tolerate chemoradiotherapy were irradiated to 60 Gy at 2 Gy/fraction with HT.</p><p>Results: The 1-, and 2-year overall survival rate were 75.0%, and 46.9%, respectively. The 1-, and 2-year locoregional recurrence-free survival rate ware 72.9%, and 72.9%, respectively. Three patients developed grade 2 or 3 hematological acute toxicity, and one patient developed grade 2 late pericardial effusion.</p><p>Conclusions: Medically inoperable patients with esophageal cancer who cannot tolerate chemoradiotherapy might be treated safely by high-dose HT with minimal adverse events.</p>

    DOI CiNii

全件表示 >>

MISC(査読の無い研究業績) 【 表示 / 非表示